Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Short Title: C3651021

Enrollment Status: Recruiting

NCT #: NCT06989437

Specialty Area: Oncology

Conditions Studied: Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma

Age Groups: Adult; Older Adult

Phase: II/III

Study Information

Summary / Purpose

To investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and mPDAC

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with metastatic pancreatic ductal adenocarcinoma and Cachexia
ECOG PS ≤1
No history of heart failure or left ventricular ejection fraction <50%
No neuroendocirne or acinar pancreatic carcinoma, symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases
No inadequate liver function or renal disease

What's Involved

Participation in the study will include:

Subcutaneous injections (injection given just under the skin) of ponsegromab or placebo every 4 weeks

Principal Investigator

Harry Menon, DO

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06989437

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews